Spojené štáty - angličtina - NLM (National Library of Medicine)

seton pharmaceuticals - folic acid (unii: 935e97boy8) (folic acid - unii:935e97boy8), .beta.-carotene (unii: 01yae03m7j) (.beta.-carotene - unii:01yae03m7j), calcium ascorbate (unii: 183e4w213w) (ascorbic acid - unii:pq6ck8pd0r), cholecalciferol (unii: 1c6v77qf41) (cholecalciferol - unii:1c6v77qf41), .alpha.-tocopherol acetate, dl- (unii: wr1wpi7ew8) (.alpha.-tocopherol, dl- - unii:7qwa1rio01), thiamine mononitrate (unii: 8k0i04919x) (thiamine ion - unii:4abt0j945j), riboflavin (unii: tlm2976ofr) (riboflavin - unii:tlm2976ofr), niacinamide (unii: 25x51i8rd4) (niacinamide - unii:25x51i8rd4), pyridoxine hydrochloride (unii: 68y4cf58bv) (pyridoxine - unii:kv2jz1bi6z), cyanocobalamin (unii: p6yc3eg204) (cyanocobalamin - unii:p6yc3eg204), calcium pantothenate (unii: 568et80c3d) (pantothenic acid - unii:19f5hk2737), calcium carbonate (unii: h0g9379fgk) (calcium cation - unii:2m83c4r6zb), ferrous fumarate (unii: r5l488ry0q) (ferrous cation - unii:gw89581owr), zinc oxide (unii: soi2loh54z) (zinc cation - unii:13s1s8sf37) - folic acid 1 mg - se-natal 19 chewable tablets are indicated for use in improving the nutritional status of women throughout pregnancy and in the postnatal period for both lactating and non-lactating mothers. se-natal 19 chewable tablets are also useful in improving the nutritional status of women prior to conception. this product is contraindicated in patients with a known hypersensitivity to any of the ingredients.

Spojené štáty - angličtina - NLM (National Library of Medicine)

seton pharmaceuticals - estrogens, conjugated (unii: iu5qr144qx) (estrogens, conjugated - unii:iu5qr144qx) - estrogens, conjugated 0.625 mg

Spojené štáty - angličtina - NLM (National Library of Medicine)

seton pharmaceuticals - azacitidine (unii: m801h13nru) (azacitidine - unii:m801h13nru) - azacitidine 100 mg

Spojené štáty - angličtina - NLM (National Library of Medicine)

seton pharmaceuticals - dapsone (unii: 8w5c518302) (dapsone - unii:8w5c518302) - dapsone 25 mg - dermatitis herpetiformis: (d.h.) leprosy: all forms of leprosy except for cases of proven dapsone resistance.

Spojené štáty - angličtina - NLM (National Library of Medicine)

seton pharmaceuticals - vitamin a palmitate (unii: 1d1k0n0vvc) (vitamin a - unii:81g40h8b0t) - vitamin a 1500 [iu] in 1 ml

Spojené štáty - angličtina - NLM (National Library of Medicine)

seton pharmaceuticals - vitamin a palmitate (unii: 1d1k0n0vvc) (vitamin a - unii:81g40h8b0t) - vitamin a 1500 [iu] in 1 ml

Spojené štáty - angličtina - NLM (National Library of Medicine)

seton pharmaceuticals - pentamidine isethionate (unii: v2p3k60da2) (pentamidine - unii:673lc5j4lq) - pentamidine isethionate 300 mg in 300 mg - pentamidine isethionate for injection is indicated for the treatment of pneumonia due to pneumocystis carinii. contraindicated in patients with a history of hypersensitivity to pentamidine isethionate.

Spojené štáty - angličtina - NLM (National Library of Medicine)

seton pharmaceuticals - salicylic acid (unii: o414pz4lpz) (salicylic acid - unii:o414pz4lpz) - salicylic acid 60 mg in 1 g

Spojené štáty - angličtina - NLM (National Library of Medicine)

seton pharmaceuticals - prednisolone sodium phosphate (unii: iv021nxa9j) (prednisolone - unii:9phq9y1olm) - prednisolone 5 mg in 5 ml

Spojené štáty - angličtina - NLM (National Library of Medicine)

seton pharmaceuticals - fluocinolone acetonide (unii: 0cd5fd6s2m) (fluocinolone acetonide - unii:0cd5fd6s2m) - fluocinolone acetonide 0.11 mg in 1 ml - fluocinolone acetonide 0.01% oil ear drops is contraindicated in those patients with a history of hypersensitivity to any of the components of the preparation. this product contains refined peanut oil nf (see precautions). pediatric use: fluocinolone acetonide 0.01% oil ear drops may be used twice daily for up to 2 weeks in pediatric patients 2 years of age and older with chronic eczematous external otitis. fluocinolone acetonide 0.01% oil ear drops is not recommended for use on the face (see adverse reaction section). because of a higher ratio of skin surface area to body mass, children are at a greater risk than adults of hpa-axis-suppression when they are treated with topical corticosteroids. they are therefore also at greater risk of glucocorticosteroid insufficiency after withdrawal of treatment and of cushing's syndrome while on treatment. adverse effects including striae have been reported with inappropriate use of topical corticosteroids in infants and children. (see precautions). hpa axis suppression, cushing's syndrome, and intracranial hypertension have been reported in children receiving topical corticosteroids. children may be more susceptible to systemic toxicity from equivalent doses due to their larger skin surface to body mass ratios. manifestations of adrenal suppression in children include linear growth retardation, delayed weight gain, low plasma cortisol levels, and absence of response to acth stimulation. manifestations of intracranial hypertension include bulging fontanelles, headaches, and bilateral papilledema. fluocinolone acetonide 0.01% oil ear drops is formulated with 48% refined peanut oil nf. peanut oil used in this product is routinely tested for peanut proteins through amino acid analysis; the quantity of amino acids is below 0.5 parts per million. physicians should use caution in prescribing fluocinolone acetonide 0.01% oil ear drops for peanut-sensitive individuals.